PMID- 36116599
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221228
IS  - 1096-1194 (Electronic)
IS  - 0890-8508 (Linking)
VI  - 66
DP  - 2022 Dec
TI  - The measurement of NRF2 and TP53 in blood expects radiotherapeutic sensitivity in 
      patients with esophageal cancer.
PG  - 101860
LID - S0890-8508(22)00071-8 [pii]
LID - 10.1016/j.mcp.2022.101860 [doi]
AB  - OBJECTIVE: This study investigates the relationship between the mRNA expression 
      of nuclear factor erythroid 2-related factor 2 (NRF2) and Tumor protein p53 
      (TP53) in circulating tumor cells (CTC) and sensitivity to radiotherapy in 
      patients with esophageal cancer. To investigate the relationship between 
      cytokines IL-6, CD8(+), and NRF2 during patient treatment and their predictive 
      role for treatment. METHODS: Radiosensitivity was assessed by measuring a 
      morphological or functional change in the tumor in response to ionizing 
      radiation. Fasting venous anticoagulated blood (EDTA anticoagulation) was drawn 
      from patients, and the Trizol-chloroform two-step method was used for RNA 
      extraction. Data were collected from 45 patients admitted with radiotherapy alone 
      from January 2018 to December 2021. The expression levels of NRF2mRNA (Messenger 
      Ribose Nucleic Acid) and TP53mRNA in CTCs were detected by reverse 
      transcription-polymerase chain reaction (RT-PCR). Pre- and post-treatment changes 
      in IL-6 and CD8(+) were recorded. The correlation between their expression level 
      and the clinical stage, radiotherapy sensitivity, and efficacy of patients was 
      analyzed. RESULTS: Twenty-six cases were sensitive to radiotherapy, and 19 were 
      resistant, for a radiotherapy sensitivity rate of 58.8%. NRF2mRNA and TP53mRNA 
      values increased in 19 radiotherapy-resistant patients and decreased in 26 
      radiotherapy-sensitive patients compared with those before radiotherapy 
      (P = 0.001, P＜0.05). The DeltaCT values of NRF2mRNA and TP53mRNA before treatment 
      were moderately correlated with prognosis (P < 0.002). Inflammatory cytokine IL-6 
      was elevated in 22 of 45 patients after radiation, P = 0.04. NRF2 mRNA level was 
      consistently elevated with CD8(+) in 10 patients, P = 0.02. CONCLUSIONS: The 
      expression of NRF2mRNA and TP53mRNA in the CTCs found in the peripheral blood of 
      patients with esophageal squamous carcinoma was significantly associated with the 
      sensitivity to radiotherapy. NRF2 mRNA level was consistently elevated with 
      CD8(+) and IL-6 in patients.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Xu, Huiqin
AU  - Xu H
AD  - Radiotherapy Center, Qilu hospital of Shandong University, Jinan city, Shandong 
      Province, 25000, China; Radiotherapy Department, The Second Affiliated Hospital 
      of Xuzhou Medical University (Xuzhou Mining Group General Hospital), Xuzhou City, 
      Jiangsu Province, 221000, China. Electronic address: 13585397309@139.com.
FAU - Wu, Jinchang
AU  - Wu J
AD  - Radiotherapy Department, The Second Affiliated Hospital of Xuzhou Medical 
      University (Xuzhou Mining Group General Hospital), Xuzhou City, Jiangsu Province, 
      221000, China.
FAU - Zhang, Lansheng
AU  - Zhang L
AD  - Radiotherapy Department, The Second Affiliated Hospital of Xuzhou Medical 
      University (Xuzhou Mining Group General Hospital), Xuzhou City, Jiangsu Province, 
      221000, China.
FAU - Li, Yang
AU  - Li Y
AD  - Radiotherapy Department, The Second Affiliated Hospital of Xuzhou Medical 
      University (Xuzhou Mining Group General Hospital), Xuzhou City, Jiangsu Province, 
      221000, China.
FAU - Gao, Liyan
AU  - Gao L
AD  - Xuzhou Medical University, Xuzhou City, Jiangsu Province, 221000, China.
FAU - Cheng, Yufeng
AU  - Cheng Y
AD  - Radiotherapy Center, Qilu hospital of Shandong University, Jinan city, Shandong 
      Province, 25000, China. Electronic address: qlcyf@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220916
PL  - England
TA  - Mol Cell Probes
JT  - Molecular and cellular probes
JID - 8709751
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (Interleukin-6)
RN  - 0 (RNA, Messenger)
RN  - 0 (TP53 protein, human)
SB  - IM
MH  - Humans
MH  - *NF-E2-Related Factor 2/genetics/metabolism
MH  - Tumor Suppressor Protein p53/genetics
MH  - Interleukin-6/genetics/metabolism
MH  - *Esophageal Neoplasms/genetics/radiotherapy/pathology
MH  - RNA, Messenger/genetics
OTO - NOTNLM
OT  - Esophageal cancer
OT  - NRF2
OT  - RT-PCR
OT  - Radiation sensitivity
OT  - Radiation therapy
OT  - TP53
COIS- Declaration of competing interest The authors declare no competing interests.
EDAT- 2022/09/19 06:00
MHDA- 2022/12/07 06:00
CRDT- 2022/09/18 19:24
PHST- 2022/05/02 00:00 [received]
PHST- 2022/08/10 00:00 [revised]
PHST- 2022/09/07 00:00 [accepted]
PHST- 2022/09/19 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/09/18 19:24 [entrez]
AID - S0890-8508(22)00071-8 [pii]
AID - 10.1016/j.mcp.2022.101860 [doi]
PST - ppublish
SO  - Mol Cell Probes. 2022 Dec;66:101860. doi: 10.1016/j.mcp.2022.101860. Epub 2022 
      Sep 16.